Skip to main content

21-09-2020 | Breast cancer | Video

ESMO 2020 | Neoadjuvant atezolizumab plus chemotherapy supported for early TNBC

Nadia Harbeck presents the IMpassion031 study showing improved pathological complete responses with the addition of atezolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer (3:51).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.